Nemaura Medical Inc. (NMRD)
| Market Cap | 65.80M |
| Revenue (ttm) | 183,628 |
| Net Income (ttm) | -12.40M |
| Shares Out | 24.10M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,153 |
| Open | 2.60 |
| Previous Close | 2.79 |
| Day's Range | 2.60 - 2.84 |
| 52-Week Range | 2.15 - 17.40 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 12.41 (+354.6%) |
| Earnings Date | Jul 5, 2022 |
About NMRD
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company was founded in 2009 and is based in New York, New York.
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NMRD stock is "Buy." The 12-month stock price forecast is 12.41, which is an increase of 354.58% from the latest price.
News
Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding
Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and suppo...
MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical's sugarBEAT Non-Invasive Continuous Gluc...
Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and suppo...
Nemaura Medical to Present at the Planet MicroCap Showcase 2022
Loughborough, England, April 25, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and sup...
Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference
Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and sup...
Nemaura Medical Wins Innovation Awards
Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearabl...
Nemaura Medical Announces Fiscal Third Quarter 2022 Financial Results and Provides Business Update
Loughborough, England, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearabl...
Nemaura Medical Launches Metabolic Health Program for Employers and Insurers
Launch into commercial markets offers opportunit ies for faster and wider adoption of Mi b o k o program
Nemaura Medical to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference
Loughborough, England, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...
Nemaura Medical Completes Initial Shipment of CGM Devices to UK Licensee
Sales in UK expected to be followed by launches across major EU territories in 2022
Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update
Loughborough, England, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...
Nemaura Medical to Present at the Diabetes Technology Society 2021 Conference on November 4, 2021
Loughborough, England, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...
Nemaura Medical to Present at the LD Micro Main Event Conference
Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...
Nemaura Medical Launches Beta Version of Its Metabolic Health Program
MiBoKo , a noninvasive glucose sensor utilizing AI mobile application, addresses a substantia l multibillion-dollar market opportunity in healthcare
Nemaura Medical Announces Commercial Agreement with UK Licensee
Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up
Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function
NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Nemaura Medical Inc. (NASDAQ: NMRD) announces the availability of a broadcast titled, “Healthcare Technologies Spearheading Modern Medic...
Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board
Loughborough, England, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...
Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021
Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...
Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021
Loughborough, England, July 12, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...
Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st...
Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...
Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2021
Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous ...
Nemaura Medical Makes Progress with Advanced Noninvasive Sensors for Diabetes Management and Metabolic Health
For millions of diabetic patients worldwide, the reality of constantly having needles pricked into the body for glucose monitoring can be a never-ending nightmare. With over 460 million people currently...
Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...
Neumaura Medical, Inc. to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
Loughborough, England, May 26, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devi...
Former Penny Stocks To Watch Making Their Mark In 2021
These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Infor...
Nemaura Medical Stages Epic Reversal
Shares of Nemaura Medical Inc. (NASDAQ:NMRD) may be about to drop even more than they have so far today. On Wednesday, the bulls were firmly in control.